FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfoli

newsfileApr 7 22:55 ET

FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With INGENu CRO

FSD Pharma Inc. (NASDAQ and CSE:HUGE), a biopharmaceutical company, was at last look up 1.4% in US premarket trade after announcing Wednesday that through its subsidiary, HUGE Biopharma Australia Pty

MT NewswiresMar 27 08:23 ET

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus

FSD Pharma Inc. (HUGE.CSE) over the holiday weekend announced that, further to its November 6 press release, and in order to replace its prior base shelf prospectus that expired, it has filed and obta

MT NewswiresDec 27, 2023 07:04 ET

FSD Pharma Inc. Announces Closing of Private Placement

TORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the "Company" or "FSD"), is pleased to announce that, further to its news release on November 27, 2023,

AccesswireDec 5, 2023 09:00 ET

Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a ne

AccesswireNov 24, 2023 07:55 ET

FSD Pharma Says Arbitration Panel Finds That Nasdaq-listed Syneos Health "Failed to Use Commercially Reasonable Efforts in Conducting Its Trial for FSD 201"

FSD Pharma Inc. (NASDAQ and CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and

MT NewswiresJul 17, 2023 17:07 ET